Brief: Hls Therapeutics Announces Q1 Fiscal 2023 Financial Results
May 11 (Reuters) - Hls Therapeutics Inc HLS.TO :
* HLS THERAPEUTICS ANNOUNCES Q1 FISCAL 2023 FINANCIAL
RESULTS
* APPOINTED CRAIG MILLIAN AS CHIEF EXECUTIVE OFFICER OF
COMPANY
* Q1 2023 REVENUE WAS $14.8 MILLION COMPARED TO $14.6
MILLION
* NET LOSS FOR Q1 2023 WAS ($0.18) PER SHARE
Source text for Eikon: ID:nCNWlRYqpa
Further company coverage: HLS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HLS Therapeutics
See all newsCanada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group
Canada's HLS Therapeutics Q1 revenue rises on Vascepa growth, reaffirms 2026 guidance
Canada's HLS Therapeutics Q4 revenue slightly beats on Vascepa strength
Brief: Esperion Partner announces HLS Therapeutics received approval Of NILEMDO for the reduction of LDL-cholesterol in canadians at risk of cardiovascular disease
Brief: HLS Therapeutics announces Health Canada approval of NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease